Contact Us
Drug Search Results
More Filters [+]

Diflunisal

Alternative Names: diflunisal, dolobid
Latest Update: 2023-09-29
Latest Update Note: News Article

Product Description

Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain, and helps to relieve symptoms of arthritis (eg, osteoarthritis and rheumatoid arthritis), including inflammation, swelling, stiffness, and joint pain. This medicine does not cure arthritis and will help you only as long as you continue to take it. (Sourced from: https://www.mayoclinic.org/drugs-supplements/diflunisal-oral-route/side-effects/drg-20069723?p=1)

Mechanisms of Action: COX1 Inhibitor,COX2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Canada | Colombia | Egypt | Germany | India | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Sweden | Taiwan | Turkey | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diflunisal

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Transthyretin Amyloidosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2019-002873-80

P3

Active, not recruiting

Transthyretin Amyloidosis

2021-12-19

Recent News Events

Date

Type

Title

09/29/2023

News Article

 Transthyretin Amyloidosis Treatment Market Size, Growth, 2023-2031

09/07/2023

News Article

 The report offers valuable insights into the regulatory landscape of the Acetylcysteine Solution For Inhalation market, covering the policies and regulations that are governing the market.

09/07/2023

News Article

 Unlocking the Potential of Dimethicone Tablets Market Scope the market's Growth Trends and Future Opportunities are growing at a CAGR of 5.2% and Forecasted the time period from 2023 to 2030

06/24/2022

News Article

 US Rx-to-OTC Switches Industry Forecasts to 2026 - Patent Expirations and Increasing Competitiveness with the Pharmaceutical Environment is Driving Growth

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions